Enfuvirtide is the first representative of a new group of antiretrovirals - fusion inhibitors, which was approved for clinical use. Due to its attachment to the HR1 domain of HIV glycoprotein gp 41 enfuvirtide blocks the fusion between the virus and the target... ...
